Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors

Hepatology

Volumn 45, Issue 3, 2007, Pages 746-754

  Chang, Chun Jung ^a   Chen, Yi Hsiang ^a   Huang, Kai Wen ^a   Cheng, Hao Wei ^a   Chan, Suit Fong ^a   Tai, Kuo Feng ^a,b   Hwang, Lih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLNITROSAMINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MONOCLONAL ANTIBODY;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; EXPERIMENTAL MODEL; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIVER TRANSPLANTATION; LIVER TUMOR; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LIVER NEOPLASMS; MACROPHAGE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR;

EID: 33947357821     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21560     Document Type: Article

References (30)

1. Carr BI, Bartlett D, Marsh JW: Cancers of the liver. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott, 2001; 1162-1195.
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353: 1253-1257.
3. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-1619.
4. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-3543.
5. Hsieh CL, Pang VF, Chen DS, Hwang LH. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum Gene Ther 1997;8:1843-1854.
6. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 1993;91:566-576.
7. Brunda MJ. Interleukin-12. J Leukoc Biol 1994;55:280-288.
8. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153:1697-1706.
9. Tai KF, Chen PJ, Chen DS, Hwang LH. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. J Gene Med 2003;5: 386-398.
10. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-2514.
11. Lee YL, Ye YL, Yu CI, Wu YL, Lai YL, Ku PH, et al. Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum Gene Ther 2001;12:2065-2079.
12. Chang CJ, Tai KF, Roffler S, Hwang LH. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J Immunol 2004;173:6025-6032.
13. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. HEPATOLOGY 2001;33:52-61.
14. Ha WS, Kim CK, Song SH, Kang CB. Study on mechanism of multistep hepatotumorigenesis in rat: development of hepatotumorigenesis. J Vet Sci 2001;2:53-58.
15. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005;202:1279-1288.
16. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol 1984;2:283-318.
17. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 2001;61:1948-1956.
18. Morikane K, Tempero R, Sivinski CL, Kitajima S, Gendler SJ, Hollingsworth MA. Influence of organ site and tumor cell type on MUC1-specific tumor immunity. Int Immunol 2001;13:233-240.
19. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340-3345.
20. Hill HC, Conway TF Jr, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: conduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002;62:7254-7263.
21. Wang Z, Qiu SJ, Ye SL, Tang ZY, Xiao X. Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther 2001;8:751-758.
22. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
23. Gillessen S, Naumov YN, Nieuwenhuis EE, Exley MA, Lee FS, Mach N, et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A 2003;100:8874-8879.
24. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-3246.
25. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med 2005;202:1623-1626.
26. Exley MA, Koziel MJ. To be or not to be NKT: natural killer T cells in the liver. HEPATOLOGY 2004;40:1033-1040.
27. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
28. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202:1627-1633.
29. Hammond KJ, Pellicci DG, Poulton LD, Naidenko OV, Scalzo AA, Baxter AG, et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001;167:1164-1173.
30. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000;21: 573-583.